title: The top 10 things nephrologists wish every primary care physician knew.
abstract: Renal disease is commonly encountered by primary care physicians during their day-to-day visits with patients. Common renal disorders include hypertension, proteinuria, kidney stones, and chronic kidney disease. Despite their prevalence, many physicians may be unfamiliar with the diagnosis and initial treatment of these common renal disorders. Early recognition and intervention are important in slowing the progression of chronic kidney disease and preventing its complications. The evidence-based pearls in this article will help primary care physicians avoid common pitfalls in the recognition and treatment of such disorders and guide their decision to refer their patients to a specialist.
authors.affiliation: Department of Medicine, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at UCLA, CA 90073, USA. neil.paige@va.gov
authors.forename: Neil M
authors.initials: NM
authors.lastname: Paige
authors.forename: Glenn T
authors.initials: GT
authors.lastname: Nagami
mesh_terms: D000535:Aluminum / Q000032:analysis; D000740:Anemia / Q000150:complications / Q000188:drug therapy; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000863:Antacids / Q000737:chemistry; D001794:Blood Pressure; D001806:Blood Urea Nitrogen; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002400:Cathartics / Q000009:adverse effects; D002908:Chronic Disease; D000075202:Contraindications; D003404:Creatinine / Q000097:blood / Q000652:urine; D016572:Cyclosporine / Q000009:adverse effects; D018450:Disease Progression; D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions; D004921:Erythropoietin / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000209:etiology; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007674:Kidney Diseases / Q000175:diagnosis* / Q000628:therapy*; D008274:Magnesium / Q000032:analysis; D053040:Nephrolithiasis / Q000150:complications; D009398:Nephrology; D010710:Phosphates / Q000009:adverse effects; D011320:Primary Health Care; D011507:Proteinuria / Q000150:complications; D011994:Recombinant Proteins; D012017:Referral and Consultation; D016559:Tacrolimus / Q000009:adverse effects; D016482:Urinalysis
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000863:Antacids; D002400:Cathartics; D007166:Immunosuppressive Agents; D010710:Phosphates; D011994:Recombinant Proteins; D004921:Erythropoietin; D016572:Cyclosporine; D003404:Creatinine; D000535:Aluminum; D008274:Magnesium; C018279:sodium phosphate; D016559:Tacrolimus